

Information for Patient

BREYANZI® may cause side effects that are life-threatening and can lead to death.

Call your oncologist or go to the emergency room right away if the following symptoms appear:

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heart rate
- Severe fatigue or weakness

© 2022 Juno Therapeutics, Inc.,
a Bristol-Myers Squibb Company. All Rights Reserved.
BREYANZI and the related logo are trademarks of Juno
Therapeutics, Inc., a Bristol-Myers Squibb Company.



Patient Wallet Card

Have this card with you at all times. Show it to any doctor who sees you and when you go to the hospital.

- Tell any healthcare provider who sees you that you are being treated with BREYANZI®.
- For at least 4 weeks after receiving BREYANZI, you should plan to stay within 2 hours of the location where you received treatment.
- Refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks after BREYANZI administration.

Name of BREYANZI® Treating Oncologist

Office Phone Number

After-hours Phone Number

Hospital Name (for Management of BREYANZI Side Effects)

Date of BREYANZI Infusion

06/22 US-REMS-BRZ190003

www.BreyanziREMS.com

Information for the Healthcare Provider

This patient has received BREYANZI® CAR T cell therapy, a CD19-directed genetically modified autologous T cell immunotherapy.



Following treatment with BREYANZI, cytokine release syndrome (CRS) or neurologic toxicities may occur, which may be fatal or life-threatening. CRS may involve any organ system.

Contact Patient's Oncologist Immediately for Further Information and in the Following Situations:

- The administration of steroids or cytotoxic medications.
- If the patient has a serious infection.
- Any planned invasive procedure(s) for the patient.